While on treatment with antineoplastic agents, mortality rates from cancer are higher in acromegaly patients whose growth hormone levels remain elevated, and those with reduced growth hormone levels have a mortality rate similar to the general population [2]. This evidence concerns the gene GH1 and acromegaly.